CoChat

Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells

Open access

The DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index.

Abstract

Abstract Background Ibrutinib is a Bruton’s tyrosine kinase (BTK) and interleukin-2-inducible kinase (ITK) inhibitor used for treating chronic lymphocytic leukaemia (CLL) and other cancers. Although ibrutinib is known to inhibit the growth of breast cancer cell growth in vitro, its impact on the treatment and metastasis of breast cancer is unclear. Methods Using an orthotopic mouse breast cancer model, we show that ibrutinib inhibits the progression and metastasis of breast cancer. Results Ibrutinib inhibited proliferation of cancer cells in vitro, and Ibrutinib-treated mice displayed significantly lower tumour burdens and metastasis compared to controls. Furthermore, the spleens and tumours from Ibrutinib-treated mice contained more mature DCs and lower numbers of myeloid-derived suppressor cells (MDSCs), which promote disease progression and are linked to poor prognosis. We also confirmed that ex vivo treatment of MDSCs with ibrutinib switched their phenotype to mature DCs and significantly enhanced MHCII expression. Further, ibrutinib treatment promoted T cell proliferation and effector functions leading to the induction of antitumour TH1 and CTL immune responses. Conclusions Ibrutinib inhibits tumour development and metastasis in breast cancer by promoting the development of mature DCs from MDSCs and hence could be a novel therapeutic agent for the treatment of breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-020-0743-8

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Ibrutinib reduces tumour growth and tumour size. Tumour cells were implanted into the mammary fat pad. Once the tumours were palpable, mice were randomised and treated with vehicle or ibrutinib once a day. Mice were euthanised at 30 days of post-implantation and harvested for tumours. a Tumour volume measured every 4 days (mean ± SE of tumour volume at each time point) are represented. b Tumour weights are represented in grams at day 30. c Representative pictures of tumours from vehicle and ibrutinib group at day 30 of harvest. d Percentage cell viability and immunoblot of BTK expression in E0.2 cells by ibrutinib treatment. Data represented are means ± SEM from 1 of the 3 successful experiments with a minimum of 10–12 mice per each group. *P < 0.05 by unpaired t test.
Fig. 1 Ibrutinib reduces tumour growth and tumour size. Tumour cells were implanted into the mammary fat pad. Once the tumours were palpable, mice were randomised and treated with vehicle or ibrutinib once a day. Mice were euthanised at 30 days of post-implantation and harvested for tumours. a Tumour volume measured every 4 days (mean ± SE of tumour volume at each time point) are represented. b Tumour weights are represented in grams at day 30. c Representative pictures of tumours from vehicle and ibrutinib group at day 30 of harvest. d Percentage cell viability and immunoblot of BTK expression in E0.2 cells by ibrutinib treatment. Data represented are means ± SEM from 1 of the 3 successful experiments with a minimum of 10–12 mice per each group. *P < 0.05 by unpaired t test.CC BY · PubMed Central
Fig. 2 Ibrutinib treatment results in the reduction of lung metastasis. Mice were euthanised from both vehicle- and ibrutinib-treated groups at day 30, and the lungs, spleens, and tumours were collected. Lungs were placed in Bouin’s solution and analysed for both large and small metastatic nodules. a The numbers of large and small metastatic nodules present on the lungs of the vehicle- and ibrutinib-treated mice are represented. b Representative lung pictures from the vehicle- and ibrutinib-treated groups. c Representative pictures of lung sections with H & E stain taken at ×200 magnification. d Spleen weights were represented in grams from vehicle- and ibrutinib-treated mice. Gene expression analysis of e Vegf, f Mmp9, and g Cxcl1 from the tumours of vehicle- and ibrutinib-treated mice. Data represented are means ± SEM from one of the three successful experiments with a minimum of five tumour samples per each group. *P < 0.05 and **P < 0.01, by unpaired t test.
Fig. 2 Ibrutinib treatment results in the reduction of lung metastasis. Mice were euthanised from both vehicle- and ibrutinib-treated groups at day 30, and the lungs, spleens, and tumours were collected. Lungs were placed in Bouin’s solution and analysed for both large and small metastatic nodules. a The numbers of large and small metastatic nodules present on the lungs of the vehicle- and ibrutinib-treated mice are represented. b Representative lung pictures from the vehicle- and ibrutinib-treated groups. c Representative pictures of lung sections with H & E stain taken at ×200 magnification. d Spleen weights were represented in grams from vehicle- and ibrutinib-treated mice. Gene expression analysis of e Vegf, f Mmp9, and g Cxcl1 from the tumours of vehicle- and ibrutinib-treated mice. Data represented are means ± SEM from one of the three successful experiments with a minimum of five tumour samples per each group. *P < 0.05 and **P < 0.01, by unpaired t test.CC BY · PubMed Central
Fig. 3 Reduced frequencies of total MDSCs and Mo-MDSCs by ibrutinib treatment. Single-cell suspensions were prepared from both groups of mice and analysed for total MDSCs (CD11b+Gr1+), monocytic MDSCs (Mo-MDSCs/CD11b+Ly6Chi), and granulocytic MDSCs (G-MDSCs/CD11b+Ly6G+) in both the spleens and tumours. a Representative gating strategy used to analyse the total MDSCs in both the spleen and tumour. b Bar graph represents the percentage of total MDSCs in total gated live cells from the spleen and tumour of vehicle- and ibrutinib-treated groups. c The proliferation of CFSE-labelled naive T cells co-cultured with CD11b+Gr1+ cells sorted from the spleens of vehicle- and ibrutinib-treated mice. d Represents the gating strategy followed to analyse the Mo-MDSCs and G-MDSCs from total CD11b+ gated live splenocytes. e Percentage of Mo-MDSCs from total CD11b+ gated live cells in the spleens and tumours of vehicle- and ibrutinib-treated mice. Data are representative of 1 of the 3 independent experiments, with 10–12 mice/group. Error bars represent means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.0001, by unpaired t test.
Fig. 3 Reduced frequencies of total MDSCs and Mo-MDSCs by ibrutinib treatment. Single-cell suspensions were prepared from both groups of mice and analysed for total MDSCs (CD11b+Gr1+), monocytic MDSCs (Mo-MDSCs/CD11b+Ly6Chi), and granulocytic MDSCs (G-MDSCs/CD11b+Ly6G+) in both the spleens and tumours. a Representative gating strategy used to analyse the total MDSCs in both the spleen and tumour. b Bar graph represents the percentage of total MDSCs in total gated live cells from the spleen and tumour of vehicle- and ibrutinib-treated groups. c The proliferation of CFSE-labelled naive T cells co-cultured with CD11b+Gr1+ cells sorted from the spleens of vehicle- and ibrutinib-treated mice. d Represents the gating strategy followed to analyse the Mo-MDSCs and G-MDSCs from total CD11b+ gated live splenocytes. e Percentage of Mo-MDSCs from total CD11b+ gated live cells in the spleens and tumours of vehicle- and ibrutinib-treated mice. Data are representative of 1 of the 3 independent experiments, with 10–12 mice/group. Error bars represent means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.0001, by unpaired t test.CC BY · PubMed Central
Fig. 4 Ibrutinib switches MDSCs to mature dendritic cells. Single-cell suspensions were prepared from both the spleens and tumours of both groups of mice and analysed for mature DCs (Ly6Clow MHCIIhi) and immature DCs (Ly6Chi MHCIIlow) cells. a Representative gating strategy followed to analyse the mature and immature DCs from total CD11C gated live splenocytes. Bar graphs represent the percentage of b mature DCs and c immature DCs from total gated CD11C+ live cells from the spleens and tumours of vehicle- and ibrutinib-treated mice. d, e Total MDSCs were sorted from the spleens of WT tumour-implanted mice and treated with DMSO or ibrutinib (1 µM) for 1 h. Cells were washed, stained with CD11C and MHCII, and analysed for DC maturation by flow cytometry. d Gating strategy followed to identify the mature DCs (CD11C+MHCII+) from the total DMSO/ibrutinib-treated MDSCs. e The bar graph represents the percentage of matured DCs from total DMSO/ibrutinib-treated MDSCs. Data are representative of 1 of the 3 independent experiments, with 10–12 mice/group. Error bars represent means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.0001, by unpaired t test.
Fig. 4 Ibrutinib switches MDSCs to mature dendritic cells. Single-cell suspensions were prepared from both the spleens and tumours of both groups of mice and analysed for mature DCs (Ly6Clow MHCIIhi) and immature DCs (Ly6Chi MHCIIlow) cells. a Representative gating strategy followed to analyse the mature and immature DCs from total CD11C gated live splenocytes. Bar graphs represent the percentage of b mature DCs and c immature DCs from total gated CD11C+ live cells from the spleens and tumours of vehicle- and ibrutinib-treated mice. d, e Total MDSCs were sorted from the spleens of WT tumour-implanted mice and treated with DMSO or ibrutinib (1 µM) for 1 h. Cells were washed, stained with CD11C and MHCII, and analysed for DC maturation by flow cytometry. d Gating strategy followed to identify the mature DCs (CD11C+MHCII+) from the total DMSO/ibrutinib-treated MDSCs. e The bar graph represents the percentage of matured DCs from total DMSO/ibrutinib-treated MDSCs. Data are representative of 1 of the 3 independent experiments, with 10–12 mice/group. Error bars represent means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.0001, by unpaired t test.CC BY · PubMed Central
Fig. 5 Ibrutinib enhances T cell proliferation and effector function of CTLs in vivo. Splenocytes were harvested from the vehicle and ibrutinib-treated mice; stained with CD3, CD4, and CD8; and analysed for IL-2, IFN-γ, TNF-α, and Granzyme B production by intracellular flow cytometry. a Expression and e mean fluorescence intensity (MFI) of IL-2, b expression and f MFI of IFN-γ, c expression and g MFI of TNF-α, d expression and h MFI of Granzyme B of CD8+ T cells from splenocytes of vehicle- and ibrutinib-treated mice. Error bars represent means ± SEM. Data are representative of 1 of the 3 independent experiments, with 10–12 mice/group. *P < 0.05, and ***P < 0.0001, by unpaired t test.
Fig. 5 Ibrutinib enhances T cell proliferation and effector function of CTLs in vivo. Splenocytes were harvested from the vehicle and ibrutinib-treated mice; stained with CD3, CD4, and CD8; and analysed for IL-2, IFN-γ, TNF-α, and Granzyme B production by intracellular flow cytometry. a Expression and e mean fluorescence intensity (MFI) of IL-2, b expression and f MFI of IFN-γ, c expression and g MFI of TNF-α, d expression and h MFI of Granzyme B of CD8+ T cells from splenocytes of vehicle- and ibrutinib-treated mice. Error bars represent means ± SEM. Data are representative of 1 of the 3 independent experiments, with 10–12 mice/group. *P < 0.05, and ***P < 0.0001, by unpaired t test.CC BY · PubMed Central
Fig. 6 Increased production of TH1 cytokines by splenocytes of ibrutinib-treated mice. Mice were euthanised at day 30, and tumours and spleens were collected from both vehicle- and ibrutinib-treated mice. Gene expression analysis of a CCL2, b NOS2, and c Arginase1 from tumours. Splenocytes were stimulated with 2 µg/ml of anti-mouse CD3/CD28 for 72 h and analysed for T cell proliferation and cytokine production. d T cell proliferation analysed by the Alamar Blue reduction method. e IFN- γ, f TNF-α, g IL-17, h IL-6, and i IL-4, and cytokine production quantified by ELISA. Data are representative of 1 of the 3 independent experiments, with 10–12 mice/group. Error bars represent means ± SEM. *P < 0.05 and **P < 0.01, by unpaired t test.
Fig. 6 Increased production of TH1 cytokines by splenocytes of ibrutinib-treated mice. Mice were euthanised at day 30, and tumours and spleens were collected from both vehicle- and ibrutinib-treated mice. Gene expression analysis of a CCL2, b NOS2, and c Arginase1 from tumours. Splenocytes were stimulated with 2 µg/ml of anti-mouse CD3/CD28 for 72 h and analysed for T cell proliferation and cytokine production. d T cell proliferation analysed by the Alamar Blue reduction method. e IFN- γ, f TNF-α, g IL-17, h IL-6, and i IL-4, and cytokine production quantified by ELISA. Data are representative of 1 of the 3 independent experiments, with 10–12 mice/group. Error bars represent means ± SEM. *P < 0.05 and **P < 0.01, by unpaired t test.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 82

Metadata

Authors
Varikuti, S., Singh, B., Volpedo, G., Ahirwar, D. K., Jha, B. K., Saljoughian, N., Viana, A. G., Verma, C., Hamza, O., Halsey, G., Holcomb, E. A., Maryala, R. J., Oghumu, S., Ganju, R. K., & Satoskar, A. R.
Affiliations
  • The Ohio State University Wexner Medical Center (US)
  • The Ohio State University (US)
Corresponding author
Satoskar, Abhay R.
Venue
British Journal of Cancer
Published
2020-02-06
Volume
122
Issue
7
Pages
1005-1013
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W3005025575
Cited by
76
References
56
Citations by year
2026: 6 · 2025: 8 · 2024: 11 · 2023: 10 · 2022: 15 · 2021: 17 · 2020: 8
FWCI
4.38
Type
journal article
Language
en
Open access
Licence
Locations
  • British Journal of Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (K01CA207599)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
ibrutinib, breast cancer, metastasis, myeloid-derived suppressor cells, dendritic cells, BTK inhibitors, tumor immunology, MHC class II expression, T cell proliferation, antitumor immunity, Th1 response, cytotoxic T lymphocytes, tumor progression
MeSH terms
Myeloid-Derived Suppressor Cells, Adenine, Animals, Breast Neoplasms, Dendritic Cells, Female, Humans, Neoplasm Metastasis, Piperidines, Disease Progression, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells. https://app.cochat.ai/papers/10.1038/s41416-020-0743-8
The paper
Varikuti, S., Singh, B., Volpedo, G., Ahirwar, D. K., Jha, B. K., Saljoughian, N., Viana, A. G., Verma, C., Hamza, O., Halsey, G., Holcomb, E. A., Maryala, R. J., Oghumu, S., Ganju, R. K., & Satoskar, A. R. (2020). Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells. British Journal of Cancer. https://doi.org/10.1038/s41416-020-0743-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.